Development of an ELISA for the detection of autoantibodies to BP230

Kromminga, Arno; Sitaru, Cassian; Hagel, Christine; Herzog, S; Zillikens, Detlef

doi:10.1016/j.clim.2003.12.007

Cited by 59 publications

(55 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The presence of multiple epitopes on BP230 for BP sera is consistent with the results in the previous studies [26,28,30]. In addition, there were two studies in which ELISA using recombinant proteins was developed [39,40].…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid

Yoshida

Hamada

Amagai

et al. 2006

Journal of Dermatological Science

138

108

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 86%

“…However, the sensitivity was 63% and specificity was 93% in their ELISA system [39]. Our ELISA is superior in both sensitivity and specificity.…”

mentioning

confidence: 90%

Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid

Yoshida

Hamada

Amagai

et al. 2006

Journal of Dermatological Science

138

108

View full text Add to dashboard Cite

“…Although recombinant proteins used in the multiplex biochip have been studied by other researches with ELISA methods [20,21,22,24,25,26,27,28,29,30], this is the first study on their use with an IIF-based biochip method.…”

Section: Discussionmentioning

confidence: 99%

Anti-Skin Specific Autoantibodies Detected by a New Immunofluorescence Multiplex Biochip Method in Patients with Autoimmune Bullous Diseases

Tampoia¹,

Zucano²,

Villalta

et al. 2012

Dermatology

View full text Add to dashboard Cite

Background: Autoimmune blistering skin diseases are a heterogeneous group of diseases characterized by autoantibodies against structural components of the skin. In pemphigus vulgaris (PV) autoantibodies react mainly with desmoglein 3 (Dsg3) alone and/or in combination with desmoglein 1 (Dsg1). In bullous pemphigoid (BP) autoantibodies target two hemidesmosomal proteins, BP180 and BP230. Objective: To evaluate the diagnostic accuracy of a new indirect immunofluorescence (IIF) multiplex biochip method for the detection of anti-skin specific autoantibodies. Methods: Sera from 36 patients with PV and from 40 patients with BP were collected. The control group included 54 patients with other skin diseases and 40 healthy subjects. The detection of circulating autoantibodies to Dsg1, Dsg3, BP230 and BP180 was performed with a new IIF multiplex biochip method and with two currently commercially available ELISA methods. Results: The multiplex IIF method showed a high diagnostic sensitivity (100%) for PV on cells transfected with Dsg3. In patients with BP, the positivity to the BP180 antigen was higher (90%) than that on monkey esophagus (50%) and on cells transfected with BP230 (40%). A good rate of agreement was observed among methods (IIF vs. ELISA) and among ELISA systems. Conclusions: The new multiplex biochip IIF method has a high diagnostic accuracy for the diagnosis of PV and BP, comparable to ELISA methods, and is able to screen autoimmune bullous diseases.

show abstract

“…The gold standard for diagnosis, as in other blistering disorders, is still direct immunoelectron microscopy. ELISA assays for BP230 and BP180 have been developed [48]. More recently, ELISA assays for BP230 and BP180 have been developed with bacterially derived recombinant proteins that may increase sensitivity for BP [49].…”

Section: Pemphigoidmentioning

confidence: 99%

What’s new in blistering disorders?

Chaudhari¹,

Marinkovich

2007

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

From the characterization of new animal models for the study of disease pathogenesis, to the demonstration of new therapeutic modalities, many developments have revolutionized the field of autoimmune bullous diseases in the past several years. This review highlights many of the significant advances that have taken place in the diagnosis, pathogenesis, and treatment options for pemphigus, pemphigoid, epidermolysis bullosa acquisita, and immunoglobulin (Ig) A-mediated bullous disorders.

show abstract

Development of an ELISA for the detection of autoantibodies to BP230

Cited by 59 publications

References 43 publications

Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid

Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid

Anti-Skin Specific Autoantibodies Detected by a New Immunofluorescence Multiplex Biochip Method in Patients with Autoimmune Bullous Diseases

What’s new in blistering disorders?

Contact Info

Product

Resources

About